All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 7th June 2017, Christophe Fermé from The Institute Gustave Roussy, France, and colleagues published in the European Journal of Cancer results of their phase III, randomized, open-label, multicenter, non-inferiority trial (NCT00005584) assessing ABVD or BEACOPPbaseline with Involved-Field Radiotherapy (IFRT) in newly diagnosed patients with stage I–II supradiaphragmatic classical Hodgkin Lymphoma (cHL) with risk factors.
The following were the defined risk factors in this study: age ≥50, stage II with 4–5 involved nodal areas, Mediastinum/Thoracic (M/T) ratio ≥0.35, no B-symptoms and Erythrocyte Sedimentation Rate (ESR) ≥50, or B-symptoms and ESR ≥30.
Between October 1998 and September 2002, 808 patients (median age, 30.7 years; range, 15–69) were randomly assigned to the control arm (6-ABVD-IFRT; n=276), or one of the two experimental arms: 4-ABVD-IFRT (n=277) or 4-BEACOPPbaseline-IFRT (n=255). Of patients who achieved a PR after chemotherapy, 71% received 36Gy with a 4Gy boost according to protocol.
Patients and treatment delivery
Responses to treatment and outcomes
Toxicity
The authors concluded that the H9-U trial of patients with early-stage supradiaphragmatic cHL and risk factors, the H9-U trial demonstrated the non-inferiority of both experimental arms (4-ABVD-IFRT or 4-BEACOPPbaseline-IFRT) compared to the reference arm (6-ABVD-IFRT). Similar EFS and OS was achieved with 4-ABVD-IFRT and 6-ABVD-IFRT (including IFRT 30Gy in both). The authors went on to state that since the time of the H9 trial design, the standard treatment strategy of early stage cHL with risk factors has changed: 4-ABVD-IFRT 30Gy has been replaced by a combination of 2-BEACOPPescalated and 2-ABVD followed by IFRT 30Gy. RT volumes have also been reduced from IFRT to involved node or involved site RT and a risk-adapted treatment strategy has been associated with response adapted treatment using early PET.
Overall, 4 cycles of ABVD and IFRT 30Gy has been a reference strategy to develop new therapies. “It remains an effective option for patients with early-stage HL and risk factors responding to chemotherapy.”
PURPOSE: For early-stage Hodgkin lymphoma (HL), optimal chemotherapy regimen and the number of cycles to be delivered remain to settle down. The H9-U trial compared three modalities of chemotherapy followed by involved-field radiotherapy (IFRT) in patients with stage I-II HL and risk factors (NCT00005584).
PATIENTS AND METHODS: Patients aged 15-70 years with untreated supradiaphragmatic HL with at least one risk factor (age ≥ 50, involvement of 4-5 nodal areas, mediastinum/thoracic ratio ≥ 0.35, erythrocyte sedimentation rate (ESR) ≥ 50 without B-symptoms or ESR ≥ 30 and B-symptoms) were eligible for the randomised, open label, multicentre, non-inferiority H9-U trial. The limit of non-inferiority was set at 10% for the difference between 5-year event-free survival (EFS) estimates. From October 1998 to September 2002, 808 patients were randomised to receive either the control arm 6-ABVD-IFRT (n = 276), or one of the two experimental arms: 4-ABVD-IFRT (n = 277) or 4-BEACOPPbaseline-IFRT (n = 255).
RESULTS: Results in the 4-ABVD-IFRT (5-year EFS, 85.9%) and the 4-BEACOPPbaseline-IFRT (5-year EFS, 88.8%) were not inferior to 6-ABVD-IFRT (5-year EFS, 89.9%): difference of 4.0% (90%CI, -0.7%-8.8%) and of 1.1% (90%CI,-3.5%-5.6%) respectively. The 5-year overall survival estimates were 94%, 93%, and 93%, respectively. Patients treated with combined modality treatment chemotherapeutic regimen comprising doxorubicin (Adriamycin), bleomycin, vincristine (Oncovin), cyclophosphamide, procarbazine, etoposide and prednisone (BEACOPP)baseline more often developed serious adverse events requiring supportive measures and hospitalisation compared with patients receiving the chemotherapeutic regimen comprising doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD).
CONCLUSIONS: The trial demonstrates that 4-ABVD followed by IFRT yields high disease control in patients with early-stage HL and risk factors responding to chemotherapy. Although non-inferior in terms of efficacy, four cycles of BEACOPPbaseline were more toxic than four or six cycles of ABVD.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox